Form 4: Amgen Executive James E. Bradner Reports Stock and Option Awards

James E. Bradner, EVP, R&D, & Chief Scientific Officer of Amgen, reports the acquisition of stock and option awards.

Summary

• On May 6, 2025, James E. Bradner, EVP, R&D, & Chief Scientific Officer of Amgen, reported transactions involving Amgen's common stock and non-qualified stock options.
• Bradner acquired 3,549 shares of common stock and disposed of some shares, resulting in a total of 29,753 shares beneficially owned.
• He also acquired 22,944 non-qualified stock options with an exercise price of $270.44, exercisable in four equal annual installments starting May 6, 2026.
• The restricted stock units (RSUs) vest in four equal annual installments of 25% each, commencing on 5/6/2026.
• Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock and option awards, indicating standard executive compensation practices.

Positives

• The acquisition of stock and options by a high-ranking executive could be interpreted as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a multi-year commitment by the executive.

Industry Context

Executive compensation in the biotechnology industry often includes stock options and restricted stock units to align management's interests with those of shareholders and incentivize long-term value creation. This filing reflects a standard practice in the industry.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the pharmaceutical and biotechnology industries.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to retain talent and drive performance.

Stakeholder Impact

• The stock and option awards could incentivize the executive to make decisions that benefit shareholders in the long term.
• Employees may view the executive's stock ownership as a sign of confidence in the company's future.

Key Dates

Keywords

Amgen, James E. Bradner, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership, Equity Incentive Plan, Executive Compensation